The FDA Has Scheduled A Type C Meeting For November 8 To Discuss Bioxcel Therapeutics' BXCL501 Serenity III Program For The Acute Treatment Of Agitation In Schizophrenia And Bipolar I And II Disorders In The At-home Setting - 8K
Portfolio Pulse from Benzinga Newsdesk
The FDA has scheduled a Type C meeting on November 8 to discuss Bioxcel Therapeutics' BXCL501 Serenity III program for the acute treatment of agitation in schizophrenia and bipolar I and II disorders in the at-home setting.

September 07, 2023 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The FDA's upcoming meeting to discuss Bioxcel Therapeutics' BXCL501 Serenity III program could potentially impact the company's stock.
The FDA's decision on Bioxcel Therapeutics' BXCL501 Serenity III program could potentially affect the company's stock price. A positive outcome could boost the stock, while a negative one could lead to a decline. However, the exact impact is uncertain until the meeting takes place.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100